Our PhD students are broadly implicated in association ADELIH. They organized a high level congress each year. The next one will take place soon the 29 & 30 March 2018
Come and join them at Chimie Paris Tech to learn more about : THE ORIGIN OF CANCER: once upon a cell…
Check the program, excellent speakers and registration details on the congress website : https://sites.google.com/site/adelihcongress2018/
FunGeST “Functional genomics of solid tumors”, directed by Jessica Zucman-Rossi, was created in 2005, as Inserm U674, it was renewed in 2009, 2014 as UMR1162, ranked “incontournable” by Inserm as a mixed structure endorsed by four entities: Inserm, Universities Paris Diderot, Paris Descartes and Paris Nord. It is currently located at the University Hematology Institute site in a building managed by the CEPH (Centre d’Etude du Polymorphisme Humain, Foundation Jean Dausset). Since January 2019, the lab take part of Centre de Recherche des Cordeliers Research Center – Inserm UMR S1138, and as been recently renewed in January 2024.
Jessica Zucman-Rossi, is professor of Medicine in Oncology (PUPHex) at the University Paris Descartes and HEGP, dedicated full-time for research. She has directed the Inserm U674, U1162, and UMRS1138 FunGeST team since 2007, and served as chairman of the Inserm scientific committee devoted to Oncology, Genetics and Bioinformatics from 2012 to 2016. She is editor at the Journal of Hepatology (2023 IF=26.8), and the executive secretary of the International Liver Cancer Association (ILCA). She is internationally recognized in the field of genomics of human cancers, and particularly in liver tumors. Since January 2019, Pr. Zucman-Rossi has been the director of the Cordeliers Research Center, and was renewed for another 5-years in 2024.
Our mission is to develop basic genomic approaches based on human tumors analyses to identify new mechanisms of tumorigenesis and to transfer this knowledge into biomarkers and therapeutic targets that could be introduced in clinical care. In particular, we aim to identify new genomic alterations and mechanisms of carcinogenesis. We also aim to identify new risk factors and genetic predispositions promoting the development of tumors. Our major fields of research are related to liver tumors, mesothelioma and HPV-related cancers, mainly in adults but also in children for liver tumors.
Our team is multidisciplinary mixing basic researchers in genomics, genetics, cell biology, and bioinformatics with clinicians.
Our major topics are all centered on “bench to bedside” discoveries and vice versa:
Our strategies are based on large tumor collections with extensive clinical annotation (PRB Hôpitaux Universitaires Paris-Seine-Saint Denis, M Ziol, and other CRB at APHP hospitals and a national network), the development of innovative integrative genomic analyses, and the transfer into clinical care for the benefit of the patients. We are also actively developing productive scientific collaborations at CRC, regional, national, international, and industrial levels.
The team include a total of 45 peoples organized in 6 groups with their founded projects: